Database of T cell-defined human tumor antigens: the 2013 update.

The plethora of tumor antigens that have been--and are still being--defined required systematization to provide a comprehensive overview of those tumor antigens that are the most relevant targets for cancer immunotherapy approaches. Here, we provide a new update of a peptide database resource that we initiated many years ago. This database compiles all human antigenic peptides described in the literature that fulfill a set of strict criteria needed to ascertain their actual "tumor antigen" nature, as we aim at guiding scientists and clinicians searching for appropriate cancer vaccine candidates (www.cancerimmunity.org/peptide). In this review, we revisit those criteria in light of recent findings related to antigen processing. We also introduce the 29 new tumor antigens that were selected for this 2013 update. Two of the new peptides show unusual features, which will be briefly discussed. The database now comprises a total of 403 tumor antigenic peptides.

[1]  P. Bruggen,et al.  Peptide database of T-cell defined tumor antigens , 2013 .

[2]  H. Rammensee,et al.  Promiscuous survivin peptide induces robust CD4+ T‐cell responses in the majority of vaccinated cancer patients , 2012, International journal of cancer.

[3]  Thomas M. Schmitt,et al.  Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. , 2012, Blood.

[4]  P. Cresswell,et al.  Inefficient exogenous loading of a tapasin‐dependent peptide onto HLA‐B*44:02 can be improved by acid treatment or fixation of target cells , 2012, European journal of immunology.

[5]  B. J. Van den Eynde,et al.  Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity. , 2012, Current opinion in immunology.

[6]  大植 祥弘.  Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients , 2012 .

[7]  J. Clements,et al.  Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients , 2012, Cancer Immunology, Immunotherapy.

[8]  P. Coulie,et al.  A MAGE‐C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy , 2011, International journal of cancer.

[9]  N. Sato,et al.  Identification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from the lung carcinoma antigen, Lengsin. , 2011, International journal of oncology.

[10]  G. Zeng,et al.  Identification of an HLA-DPB1*0501 Restricted Melan-A/MART-1 Epitope Recognized by CD4+ T Lymphocytes: Prevalence for Immunotherapy in Asian Populations , 2011, Journal of immunotherapy.

[11]  X. Qian,et al.  Identification of promiscuous HLA‐DR‐restricted CD4+ T‐cell epitopes on the cancer‐testis antigen HCA587 , 2011, Cancer science.

[12]  T. Sawada,et al.  Identification of HLA-A*0201- and A*2402-Restricted Epitopes of Mucin 5AC Expressed in Advanced Pancreatic Cancer , 2011, Pancreas.

[13]  P. Moss,et al.  Dominant responses with conservation of T-cell receptor usage in the CD8+ T-cell recognition of a cancer testis antigen peptide presented through HLA-Cw7 in patients with multiple myeloma , 2011, Cancer Immunology, Immunotherapy.

[14]  S. Rosenberg,et al.  An antigenic peptide produced by reverse splicing and double asparagine deamidation , 2011, Proceedings of the National Academy of Sciences.

[15]  S. Stevanović,et al.  A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4+ and CD8+ T-cell as well as B-cell responses , 2011, Cancer Immunology, Immunotherapy.

[16]  D. Maloney,et al.  Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma , 2011, Cancer Immunology, Immunotherapy.

[17]  Yusuke Nakamura,et al.  A novel tumor‐associated antigen, cell division cycle 45‐like can induce cytotoxic T‐lymphocytes reactive to tumor cells , 2011, Cancer science.

[18]  B. J. Van den Eynde,et al.  Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes , 2011, Cellular and Molecular Life Sciences.

[19]  P. Coulie,et al.  Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. , 2011, Cancer research.

[20]  B. J. Van den Eynde,et al.  Differences in the production of spliced antigenic peptides by the standard proteasome and the immunoproteasome , 2011, European journal of immunology.

[21]  S. Senju,et al.  Peptides derived from human insulin‐like growth factor‐II mRNA binding protein 3 can induce human leukocyte antigen‐A2‐restricted cytotoxic T lymphocytes reactive to cancer cells , 2011, Cancer science.

[22]  Y. Nakamura,et al.  Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer , 2010, British Journal of Cancer.

[23]  A. Rogel,et al.  A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination , 2011, Cancer Immunology, Immunotherapy.

[24]  D. Schadendorf,et al.  Screening of Human Tumor Antigens for CD4+ T Cell Epitopes by Combination of HLA-Transgenic Mice, Recombinant Adenovirus and Antigen Peptide Libraries , 2010, PloS one.

[25]  B. J. Van den Eynde,et al.  Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules , 2010, Proceedings of the National Academy of Sciences.

[26]  B. J. Van den Eynde,et al.  Splicing of Distant Peptide Fragments Occurs in the Proteasome by Transpeptidation and Produces the Spliced Antigenic Peptide Derived from Fibroblast Growth Factor-5 , 2010, The Journal of Immunology.

[27]  B. Dréno,et al.  MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency , 2008, The Journal of experimental medicine.

[28]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 2007, Journal of immunology.

[29]  Anne M Evans,et al.  Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy , 2006, Proceedings of the National Academy of Sciences.

[30]  Jeffrey K. Mito,et al.  An Antigen Produced by Splicing of Noncontiguous Peptides in the Reverse Order , 2006, Science.

[31]  S. Senju,et al.  Identification of HLA-A2- or HLA-A24-Restricted CTL Epitopes Possibly Useful for Glypican-3-Specific Immunotherapy of Hepatocellular Carcinoma , 2006, Clinical Cancer Research.

[32]  B. Monsarrat,et al.  Destructive Cleavage of Antigenic Peptides Either by the Immunoproteasome or by the Standard Proteasome Results in Differential Antigen Presentation1 , 2006, The Journal of Immunology.

[33]  B. J. Van den Eynde,et al.  A peptide derived from melanocytic protein gp100 and presented by HLA-B35 is recognized by autologous cytolytic T lymphocytes on melanoma cells. , 2005, Tissue antigens.

[34]  T. Boon,et al.  An Antigenic Peptide Produced by Peptide Splicing in the Proteasome , 2004, Science.

[35]  Jonathan W. Yewdell,et al.  Immune recognition of a human renal cancer antigen through post-translational protein splicing , 2004, Nature.

[36]  S. Rosenberg,et al.  Identification of BING-4 Cancer Antigen Translated From an Alternative Open Reading Frame of a Gene in the Extended MHC Class II Region Using Lymphocytes From a Patient With a Durable Complete Regression Following Immunotherapy , 2002, The Journal of Immunology.

[37]  R. Kridel,et al.  Frame of the Human Macrophage Colony-stimulating Factor Gene Is Independently Translated and Codes for an Antigenic Peptide of 14 Amino Acids Recognized by Tumor-infiltrating CD 8 T Lymphocytes , 2001 .

[38]  Forest M. White,et al.  Phosphorylated Peptides Are Naturally Processed and Presented by Major Histocompatibility Complex Class I Molecules in Vivo , 2000, The Journal of experimental medicine.

[39]  P. Bruggen,et al.  A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. , 2000, Cancer research.

[40]  V Brusic,et al.  NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. , 2000, Cancer research.

[41]  A. Moreau-Aubry,et al.  A Processed Pseudogene Codes for a New Antigen Recognized by a Cd8+ T Cell Clone on Melanoma , 2000, The Journal of experimental medicine.

[42]  V. Brusic,et al.  NY-ESO-1 Encodes DRB 1 * 0401-restricted Epitopes Recognized by Melanoma-reactive CD 4 1 T Cells 1 , 2000 .

[43]  P. Bruggen,et al.  Advances in Brief A MAGE-A 3 Peptide Presented by HLA-DP 4 Is Recognized on Tumor Cells by CD 4 1 Cytolytic T Lymphocytes 1 , 2000 .

[44]  M. Probst-Kepper,et al.  A New Antigen Recognized by Cytolytic T Lymphocytes on a Human Kidney Tumor Results from Reverse Strand Transcription , 1999, The Journal of experimental medicine.

[45]  F. Triebel,et al.  A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. , 1999, Journal of immunology.

[46]  N. Shastri,et al.  Presentation of out-of-frame peptide/MHC class I complexes by a novel translation initiation mechanism. , 1999, Immunity.

[47]  A. Eggermont,et al.  Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes , 1999, The Journal of experimental medicine.

[48]  P. Parham,et al.  Hepatitis C virus envelope glycoprotein E1 originates in the endoplasmic reticulum and requires cytoplasmic processing for presentation by class I MHC molecules. , 1999, Journal of immunology.

[49]  S. Rosenberg,et al.  The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. , 1997, Journal of immunology.

[50]  S. Rosenberg,et al.  Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen , 1996, The Journal of experimental medicine.

[51]  P. Bruggen,et al.  Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.

[52]  F. Brasseur,et al.  A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N- acetylglucosaminyltransferase V gene , 1996, The Journal of experimental medicine.

[53]  J. Shabanowitz,et al.  An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins , 1996, The Journal of experimental medicine.

[54]  P. Coulie,et al.  A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[55]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.